Analysis of the Antibiotic Resistance Market Reveals Significant Opportunities Amidst Rising Antimicrobial Challenges - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides & Customization. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering.

In the face of growing antimicrobial resistance (AMR), a comprehensive analysis of the antibiotic resistance market highlights the advent of new infection strains and 'superbugs' that elude current antibiotic treatments. This resistance underscores the urgent demand for innovative therapeutic approaches and has catalyzed the development of new technologies targeting the burgeoning market.

Technological Advancements in AMR

The analysis provides a lucid understanding of various methodologies that address the treatment of pathogens and infections. It underscores the crucial role diagnostics will play in revolutionizing treatments and managing the threats posed by AMR. This strategic insight is critical for stakeholders aiming to navigate the complexities of this evolving landscape.

Emerging Market Opportunities

The study identifies six key opportunities that present significant potential within this sector. These burgeoning opportunities are buttressed by the advancements in understanding and treating resistant infections, reflecting a dynamic ecosystem ripe for investment.

Industry Landscape

With the proliferation of biotechnology enterprises engaging in the AMR space, the report provides a cohesive summary of over 100 entities, detailing their technological forays and strategic positions within the market. This extensive industry profiling is indicative of both the competitive nature of the market and the collaborative effort required to address AMR effectively.

Leveraging the latest data, the analysis offers precise market forecasts extending five years into the future. These projections are instrumental for stakeholders making informed decisions and valuations within the antibiotic resistance market, providing them with a grounded perspective on potential trends and shifts that may influence the sector.

As AMR continues to pose significant global health challenges, the antibiotic resistance market is undergoing a critical transformation.

Key Topics Covered:

1 Market Guides

2 Introduction and Market Definition
2.1 The Growing Threat and Opportunity of Antimicrobial Resistance
2.2 Defining the Opportunity
2.2.1 Revenue Market Size
2.3 Methods and Sources
2.4 U.S. Antibiotic Markets - Perspective

3 Overview of a Dynamic Market
3.1 Market Players - Roles & Impacts
3.2 Understanding Antimicrobial Resistance
3.3 The Changing Road to New Antibiotics & Technologies
3.4 The Key Role of Diagnostics in AMR

4 The Market Opportunity of AMR
4.1 The Key Large Market Opportunities in AMR
4.2 Therapeutic Technology Development Opportunities
4.2.1 Using Viruses Against Bacteria
4.2.2 Hydrolytic Enzymes Join the Fight
4.2.3 Antibodies
4.2.4 Vaccines
4.2.5 Probiotic Technology
4.2.6 Peptides vs. Pathogens
4.2.7 Mining Obsolete Science
4.2.8 CRISPR Antibiotics

5 Antibiotic Resistance Recent Developments
5.1 Recent Developments
5.2 Bacteriophage May Combat AMR
5.3 Shionogi to Acquire Qpex Biopharma
5.4 Adaptive Phage Therapeutics to Fight Antibiotic Resistance
5.5 Smartbax to create next-generation antibiotics
5.6 Startup Solu raises €1M to combat AMR
5.7 Akthelia Pharma and University of Iceland to Combat AMR
5.8 WHO warns of too few new Antibiotics
5.9 Bactobio Raises £6 Million To Discover Novel Antimicrobials
5.10 AMR triggers race to develop phages
5.11 AMR Pandemic Overlooked
5.12 New resistance-busting antibiotic combination
5.13 CDC Awards $22M to Combat Antimicrobial Resistance
5.14 Antibiotic resistance outwitted by supercomputers
5.15 STIs Reach Record Highs
5.16 New research using nanoparticles to bolster waning antibiotics
5.17 OpGen Receives FDA Clearance for AMR Panel
5.18 CDC Updates STI Diagnosis, Treatment Guidelines
5.19 Positive associations between AM use in animals and AMR in humans
5.20 PEW Antibiotic Pipeline Findings

6 Key Biotechnology Companies and Their Technology

7 Global Market Size
7.1 Global Market by Country
7.2 Global Market by Pathogen
7.3 Global Market by Technology

8 Market Sizes by Pathogen
8.1 DRSP Market
8.2 DRC Market
8.3 CD Market
8.4 MRSA Market
8.5 DRNG Market
8.6 DRNTS Market
8.7 Other Pathogen Market

9 Market Sizes by Technology
9.1 Antibiotics Market
9.2 Phage Market
9.3 Pep/Lys Market
9.4 Antibodies Market
9.5 Vaccine Market
9.6 Other Technology Market

10 The Future of AMR

Companies Featured

• Melinta Therapeutics
• Arsanis
• Phage Technologies S.A
• Westway Health
• Tetraphase Pharmaceuticals
• BioVersys GmbH
• Nabriva Therapeutics
• Macrolide Pharmaceuticals
• Nemesis Bioscience
• C3J Therapeutics, Inc.
• EpiBiome
• discuva
• SmartPhage.
• AmpliPhi Biosciences
• Pherecydes Pharma
• Micreos
• Procarta Biosystems
• Lumavita
• Madam Therapeutics
• Priaxon
• Biolytx Pharmaceuticals
• AntibioTx
• Xellia Pharmaceuticals
• Paratek Pharmaceuticals
• Synereca Pharmaceuticals
• Allecra Therapeutics
• Fixed Phage
• Enanta Pharmaceuticals, Inc.
• Demuris
• Prommune
• Biosergen
• Innovation Pharmaceuticals
• Aviragen Therapeutics
• Achillion Pharmaceuticals
• ImmunNovative Developments, S.L.
• Achaogen, Inc.
• SelectX Pharmaceuticals, Inc.
• TaiGen Biotechnology Co., Ltd.
• Theravance Biopharma
• Abbvie
• KYORIN Pharmaceutical Co., Ltd.
• Iterum Therapeutics Limited
• Forge Therapeutics
• Alopexx Vaccine LLC
• Integrated Biotherapeutics
• Hennepin Life Sciences
• Fedora Pharmaceuticals Inc.
• Contrafect Corporation
• Basilea Pharmaceutica Ltd.
• AiCuris
• RedHill Biopharma
• Redx Pharma Plc/Redx Anti Infectives Ltd.
• ABAC Therapeutics
• Alaxia SAS
• Antabio S.A.S
• Auspherix Ltd
• BioFilm Pharma
• Centauri Therapeutics Ltd
• Combioxin SA
• Da Volterra
• Debiopharm International SA
• Deinobiotics/Deinove
• Destiny Pharma plc
• Eligo Bioscience
• Helperby Therapeutics Ltd
• Karveel Pharmaceuticals
• MaaT Pharma
• Motif BioSciences, Inc/Motif Bio PLC
• Mutabilis SAS
• Neem Biotech Ltd
• Northern Antibiotics Oy (Ltd)
• Nosopharm
• NovaBiotics Ltd
• Phico Therapeutics Ltd
• Polyphor Ltd
• QureTech Bio AB
• SetLance srl
• Ultupharma AB
• Vaxdyn
• Vibiosphen
• Bioaster
• Vivexia
• KBP Biosciences
• Absynth Biologics
• Spero Therapeutics
• Merck
• Symphogen
• Warp Drive Bio.
• Johnson & Johnson (Janssen)
• Pfizer
• Allergan
• GlaxoSmithKline
• Novartis
• Gilead Sciences
• AstraZeneca
• Sanofi
• Shionogi Inc.
• Cipla
• DSM Sinochem Pharmaceuticals
• Wockhardt Ltd.
• VenatoRx Pharmaceuticals
• MicuRx
• Entasis Therapeutics
• Merlion Pharmaceuticals
• Aridis Pharmaceuticals Inc.

For more information about this report visit https://www.researchandmarkets.com/r/j0v8pw

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.